hVIVO plc (FRA:CRO)

Germany flag Germany · Delayed Price · Currency is EUR
0.0710
-0.0210 (-22.83%)
At close: Oct 21, 2025
-22.83%
Market Cap54.94M
Revenue (ttm)63.54M
Net Income (ttm)6.16M
Shares Outn/a
EPS (ttm)0.01
PE Ratio8.91
Forward PEn/a
Dividend0.00 (3.35%)
Ex-Dividend DateMay 15, 2025
Volumen/a
Average Volume150
Open0.0700
Previous Close0.0920
Day's Range0.0700 - 0.0905
52-Week Range0.0710 - 2.6840
Betan/a
RSI38.30
Earnings DateDec 24, 2025

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C... [Read more]

Industry Commercial Physical and Biological Research
CEO Yamin Khan
Employees 301
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol CRO
Full Company Profile

Financial Performance

In 2024, hVIVO's revenue was 66.22 million, an increase of 12.87% compared to the previous year's 58.67 million. Earnings were 10.65 million, a decrease of -33.90%.

Financial numbers in GBP Financial Statements

News

There is no news available yet.